Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Ann Endocrinol (Paris) ; 71(3): 206-9, 2010 May.
Article in English | MEDLINE | ID: mdl-20362966

ABSTRACT

Ovarian hyperstimulation syndrome (OHSS) is usually a complication of assisted reproductive techniques, more rarely an affection complicating a spontaneous gestation. The cause of hyper responsiveness of ovaries to the gonadotropins used in the controlled stimulation is still largely unknown. In contrast, a few cases of spontaneous hyperstimulation syndrome have been elucidated by the identification of mutations of the follicle-stimulating hormone (FSH) receptor, broadening its specificity and making it hypersensitive to human chorionic gonadotropin (hCG). Surprisingly, the mutations were located in the transmembrane domain of the receptor rather than in the extracellular hormone-binding site. No such mutation has been found in iatrogenic cases. However, allelic variants of the FSH receptors have been associated with the response to FSH in stimulation procedures, as well as with the severity of OHSS when present.


Subject(s)
Mutation , Ovarian Hyperstimulation Syndrome/genetics , Receptors, FSH/genetics , Chorionic Gonadotropin/physiology , Cyclic AMP/physiology , Female , Follicle Stimulating Hormone/physiology , Genetic Variation , Humans
2.
Cell Death Differ ; 15(8): 1318-29, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18421301

ABSTRACT

Resveratrol, a polyphenol found in grapes and other fruit and vegetables, is a powerful chemopreventive and chemotherapeutic molecule potentially of interest for the treatment of breast cancer. The human breast cancer cell line MCF-7, which is devoid of caspase-3 activity, is refractory to apoptotic cell death after incubation with resveratrol. Here we show that resveratrol arrests cell proliferation, triggers death and decreases the number of colonies of cells that are sensitive to caspase-3-dependent apoptosis (MCF-7 casp-3) and also those that are unresponsive to it (MCF-7vc). We demonstrate that resveratrol (i) acts via multiple pathways to trigger cell death, (ii) induces caspase-dependent and caspase-independent cell death in MCF-7 casp-3 cells, (iii) induces only caspase-independent cell death in MCF-7vc cells and (iv) stimulates macroautophagy. Using BECN1 and hVPS34 (human vacuolar protein sorting 34) small interfering RNAs, we demonstrate that resveratrol activates Beclin 1-independent autophagy in both cell lines, whereas cell death via this uncommon form of autophagy occurs only in MCF-7vc cells. We also show that this variant form of autophagic cell death is blocked by the expression of caspase-3, but not by its enzymatic activity. In conclusion, this study reveals that non-canonical autophagy induced by resveratrol can act as a caspase-independent cell death mechanism in breast cancer cells.


Subject(s)
Apoptosis Regulatory Proteins/metabolism , Autophagy , Breast Neoplasms/pathology , Membrane Proteins/metabolism , Stilbenes/pharmacology , Vesicular Transport Proteins/metabolism , Apoptosis/drug effects , Autophagy-Related Protein 7 , Beclin-1 , Breast Neoplasms/metabolism , Caspase 3/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Humans , RNA, Small Interfering/metabolism , Resveratrol , Signal Transduction , Ubiquitin-Activating Enzymes/metabolism
3.
J Clin Endocrinol Metab ; 88(8): 3491-8, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12915623

ABSTRACT

Inactivating mutations of the FSH receptor have been described in rare cases of premature ovarian failure. Only one mutation was associated with a complete phenotype, including delayed puberty, primary amenorrhea, and small ovaries. We describe here a new patient presenting a similar complete phenotype of premature ovarian failure, with high plasma FSH levels associated with very low estrogen and inhibin B levels. No biological response to high doses of recombinant FSH was detected. A novel homozygous Pro(519)Thr mutation was found in this patient. This mutation is located in the second extracellular loop of the FSH receptor, within a motif highly conserved in gonadotropin and TSH receptors. The mutation totally impairs adenylate cyclase stimulation in vitro. FSH binding experiments and confocal microscopy showed that this mutation alters the cell surface targeting of the mutated receptor, which remains trapped intracellularly. Histological studies of the ovaries of the patient showed an increase in the density of small follicles compared with age-matched normal women. A complete block in follicular maturation after the primary stage was also observed. Immunocytochemical studies allowed detection of the expression of c-Kit and proliferation cellular nuclear antigen, whereas no apoptosis was shown by the 3'-end-labeling method. This observation supports the concept that in humans FSH seems mandatory for the initiation of follicular growth only after the primary stage. In our patient complete FSH resistance yields infertility, which is remarkably associated with the persistence of a high number of small follicles.


Subject(s)
Amenorrhea/genetics , Mutation/physiology , Puberty, Delayed/genetics , Receptors, FSH/genetics , Adult , Amenorrhea/complications , Amenorrhea/pathology , Amino Acid Substitution , Animals , COS Cells , Chlorocebus aethiops , DNA/chemistry , DNA/genetics , Exons/genetics , Female , Fluorescent Antibody Technique , Follicle Stimulating Hormone/blood , Genetic Vectors , Humans , Immunohistochemistry , Microscopy, Confocal , Ovary/pathology , Puberty, Delayed/complications , Puberty, Delayed/pathology , Transfection
4.
Mol Endocrinol ; 13(11): 1844-54, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10551778

ABSTRACT

Premature ovarian failure occurs in almost 1% of women under age 40. Molecular alterations of the FSH receptor (FSHR) have recently been described. A first homozygous mutation of the FSHR was identified in Finland. More recently, we described two new mutations of the FSHR in a woman presenting a partial FSH-resistance syndrome (patient 1). We now report new molecular alterations of the FSHR in another woman (patient 2) who presented at the age of 19 with primary amenorrhea contrasting with normal pubertal development. She had high plasma FSH, and numerous ovarian follicles up to 3 mm in size were evidenced by ultrasonography. Histological and immunohistochemical examination of ovarian biopsies revealed the presence of a normal follicular development up to the antral stage and disruption at further stages. DNA sequencing showed two heterozygous mutations: Asp224Val in the extracellular domain and Leu601Val in the third extracellular loop of FSHR. Cells transfected with expression vectors encoding the wild type or the mutated Leu601Val receptors bound hormone with similar affinity, whereas binding was barely detectable with the Asp224Val mutant. Confocal microscopy showed the latter to have an impaired targeting to the cell membrane. This was confirmed by its accumulation as a mannose-rich precursor. Adenylate cyclase stimulation by FSH of the Leu601Val mutant receptor showed a 12+/-3% residual activity, whereas in patient 1 a 24+/-4% residual activity was detected for the Arg573Cys mutant receptor. These results are in keeping with the fact that estradiol and inhibin B levels were higher in patient 1 and that stimulation with recombinant FSH did not increase follicular size, estradiol, or inhibin B levels in patient 2 in contrast to what was observed for patient 1. Thus, differences in the residual activity of mutated FSHR led to differences in the clinical, biological, and histological phenotypes of the patient.


Subject(s)
Amenorrhea/genetics , Mutation , Ovary/physiopathology , Receptors, FSH/genetics , Adenylyl Cyclases/drug effects , Adenylyl Cyclases/metabolism , Adult , Amenorrhea/drug therapy , Animals , COS Cells/drug effects , COS Cells/metabolism , Female , Follicle Stimulating Hormone/pharmacology , Follicle Stimulating Hormone/therapeutic use , Gene Silencing , Humans , Immunohistochemistry , Male , Ovary/diagnostic imaging , Ovary/pathology , Phenotype , Primary Ovarian Insufficiency/drug therapy , Primary Ovarian Insufficiency/genetics , Protein Processing, Post-Translational , Receptors, FSH/drug effects , Receptors, FSH/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Analysis , Ultrasonography
5.
J Soc Biol ; 193(2): 139-45, 1999.
Article in French | MEDLINE | ID: mdl-10451347

ABSTRACT

Gonadotropin and TSH receptors belong to a subgroup of G protein-coupled receptors. TSH and FSH receptor present a particular intracellular traffic: they present a polarized basolateral expression in thyroid follicular cells and in Sertoli cells respectively. By contrast, the LH receptor is expressed circumferentially in target gonadic cells. We expressed these receptors in MDCK cells (a well characterized model of polarized epithelial cells) to understand this difference of properties. We show that the three receptors have a polarized basolateral expression in these cells. All contain a basolateral targeting signal. Furthermore, gonadotropin receptors undergo a partial transcytosis which is not observed for the TSH receptor. We show that heterotrimeric G proteins play a role in this mechanism of transcytosis. This effect is not mediated by adenylate cyclase activation and involves a population of G proteins different from that involved in signal transduction. We thus used in vitro mutagenesis to delineate the basolateral localization signal of the FSH receptor. Surprisingly, the signal is localized in the C-terminal tail of the intracellular domain which is not conserved between the three receptors. It contains 14 amino-acids and its activity is mainly dependent on a tyrosine and a leucine residue. The basolateral localization signal of the FSHR is not colinear with its internalization signal. This signal is autonomous and dominant because, when transferred to an apically targeted membrane protein, the neurotrophin receptor, it redirects the chimeric construct to the basolateral domain of MDCK cells. The basolateral localization signal of the FSH receptor is thus the first signal identified for a G protein-coupled receptor and more generally for a hormone receptor.


Subject(s)
Cell Membrane/metabolism , Ovarian Follicle/metabolism , Receptors, FSH/metabolism , Sertoli Cells/metabolism , Animals , Biological Transport , Cell Line , Cell Polarity , Female , GTP-Binding Proteins/metabolism , Male , Receptors, FSH/chemistry , Receptors, FSH/genetics , Receptors, LH/chemistry , Receptors, LH/genetics , Receptors, LH/metabolism , Receptors, Thyrotropin/chemistry , Receptors, Thyrotropin/genetics , Receptors, Thyrotropin/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Signal Transduction , Transfection
6.
Ann Endocrinol (Paris) ; 60(2): 89-92, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10456178

ABSTRACT

Gonadotropin receptors belong to a subgroup of G-protein coupled receptors characterized by a large extracellular domain responsible for the binding of the hormone. Soluble, hormone-binding, alternative splicing variants of the LH receptor, are present in high concentration. A mannose rich precursor form of LH and FSH receptor is accumulated inside target cells. FSH receptors are addressed to the basolateral domain of cells through specific signaling mechanisms. Gonadotropin receptors are also present in endothelial cells of target organ vessels and are involved in hormone transcytosis. Various genetic abnormalities of these receptors (and of the GnRH receptor) are discussed.


Subject(s)
Receptors, FSH , Receptors, LH , Animals , Humans , Receptors, FSH/analysis , Receptors, FSH/chemistry , Receptors, FSH/physiology , Receptors, LH/analysis , Receptors, LH/chemistry , Receptors, LH/physiology
7.
J Biol Chem ; 274(1): 101-7, 1999 Jan 01.
Article in English | MEDLINE | ID: mdl-9867816

ABSTRACT

The thyrotropin (TSH) receptor belongs to a subfamily of G protein-coupled receptors, which also includes luteinizing hormone and follicle-stimulating hormone receptors. The TSH receptor (TSHR) differs from the latter by the presence of an additional specific segment in the C-terminal part of its ectodomain. We show here that this insertion is excised in the majority of receptor molecules. Preparation of specific monoclonal antibodies to this region, microsequencing, enzyme-linked immunosorbent assay, and immunoblot studies have provided insight into the mechanisms of this excision. In the human thyroid gland, N termini of the transmembrane receptor beta subunit were found to be phenylalanine 366 and leucines 370 and 378. In transfected L cells a variety of other more proximal N termini were found, probably corresponding to incomplete excisions. The most extreme N terminus was observed to lie at Ser-314. These observations suggest that after initial cleavage at Ser-314 the inserted fragment of TSHR is progressively clipped out by a series of cleavage reactions progressing up to amino acids 366-378. The impossibility of recovering the excised fragment from purified receptor, cell membranes, or culture medium supports this interpretation. The cleavage enzyme has previously been shown to be inhibited by BB-2116, an inhibitor of matrix metalloproteases. However, we show here that it is unaffected by tissue inhibitors of metalloproteases. The cleavage enzyme is very similar to TACE (tumor necrosis factor alpha-converting enzyme) in both these characteristics. However, incubation of the TSH receptor with the purified recombinant catalytic domain of TACE, co-transfection of cells with TACE and TSHR expression vectors, and the use of mutated Chinese hamster ovary cells in which TACE is inactive suggested that the TSHR cleavage enzyme is different from TACE. TACE and TSHR cleavage enzyme may thus possibly be related but different members of the adamalysin family of metzincin metalloproteases.


Subject(s)
Receptors, Thyrotropin/metabolism , Animals , Antibodies, Monoclonal/immunology , CHO Cells , Cell Membrane/metabolism , Cricetinae , Culture Media , Hydrolysis , Receptors, Thyrotropin/antagonists & inhibitors , Receptors, Thyrotropin/immunology , Tissue Inhibitor of Metalloproteinases/pharmacology
8.
J Clin Invest ; 102(7): 1352-9, 1998 Oct 01.
Article in English | MEDLINE | ID: mdl-9769327

ABSTRACT

A single natural loss of function mutation of the follicle stimulating hormone receptor (FSHR) has been described to date. Present in the Finnish population it markedly impairs receptor function, blocking follicle development at the primary stage and presenting as primary amenorrhea with atrophic ovaries. When Western European women with this phenotype were examined for FSHR mutations the result was negative, suggesting that other etiologies corresponding to this clinical pattern are markedly more frequent. We now describe a novel phenotype related to mutations provoking a partial loss of function of the FSHR. A woman with secondary amenorrhea had very high plasma gonadotropin concentrations (especially FSH), contrasting with normal sized ovaries and antral follicles up to 5 mm at ultrasonography. Histological and immunohistochemical examination of the ovaries showed normal follicular development up to the small antral stage and a disruption at further stages. The patient was found to carry compound heterozygotic mutations of the FSHR gene: Ile160Thr and Arg573Cys substitutions located, respectively, in the extracellular domain and in the third intracellular loop of the receptor. The mutated receptors, when expressed in COS-7 cells, showed partial functional impairment, consistent with the clinical and histological observations: the first mutation impaired cell surface expression and the second altered signal transduction of the receptor. This observation suggests that a limited FSH effect is sufficient to promote follicular growth up to the small antral stage. Further development necessitates strong FSH stimulation. The contrast between very high FSH levels and normal sized ovaries with antral follicles may thus be characteristic of such patients.


Subject(s)
Amenorrhea/genetics , Infertility, Female/genetics , Point Mutation , Receptors, FSH/genetics , Adult , Amenorrhea/blood , Amenorrhea/diagnostic imaging , Amino Acid Sequence , Amino Acid Substitution , Animals , Base Sequence , COS Cells , Cattle , Cell Membrane/physiology , Europe , Female , Finland , Follicle Stimulating Hormone/blood , Follicle Stimulating Hormone/metabolism , Heterozygote , Humans , Infertility, Female/blood , Kinetics , Male , Mice , Models, Molecular , Ovary/diagnostic imaging , Ovary/pathology , Pedigree , Phenotype , Protein Conformation , Rats , Receptors, FSH/biosynthesis , Receptors, FSH/physiology , Recombinant Proteins/biosynthesis , Sequence Alignment , Sequence Homology, Amino Acid , Sheep , Signal Transduction , Swine , Transfection , Ultrasonography
9.
J Biol Chem ; 273(29): 18610-6, 1998 Jul 17.
Article in English | MEDLINE | ID: mdl-9660834

ABSTRACT

The follicle-stimulating hormone receptor (FSHR) is physiologically localized in the basolateral compartment of the membrane of Sertoli cells. This localization is also observed when the receptor is experimentally expressed in Madin-Darby canine kidney cells. We thus used in vitro mutagenesis and transfection into these polarized cells to delineate the basolateral localization signal of the receptor. The signal was localized in the C-terminal tail of the intracellular domain (amino acids 678-691) at a marked distance of the membrane. Mutation of individual amino acids highlighted the importance of Tyr684 and Leu689. The 14-amino acid sequence was grafted onto the p75 neurotrophin receptor and redirected this apical protein to the basolateral cell membrane compartment. Deletion of amino acids 677-695 did not modify the internalization of the FSHR, showing that the basolateral localization signal of the FSHR is not colinear with its internalization signal.


Subject(s)
Receptors, FSH/physiology , Signal Transduction/physiology , Amino Acid Sequence , Animals , COS Cells , Cell Line , Cell Membrane/metabolism , Cell Polarity , Dogs , Endocytosis , Follicle Stimulating Hormone/metabolism , GTP-Binding Protein alpha Subunits, Gs/physiology , Male , Molecular Sequence Data , Mutagenesis, Site-Directed , Point Mutation , Receptors, FSH/genetics , Sertoli Cells/cytology , Sertoli Cells/metabolism
11.
Baillieres Clin Endocrinol Metab ; 12(1): 35-66, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9890061

ABSTRACT

Over the past few years, knowledge of the structure of gonadotropin receptors and their mode of action has rapidly advanced. The cDNA corresponding to the luteinizeng hormone (LH) receptor (LHR) has been cloned, leading to the identification of a novel family of G-protein-coupled receptors. The follicle stimulating hormone (FSH) receptor (FSHR) was thereafter cloned by cross-hybridization with the LHR. Structure-function relationships have been studied by mutagenesis experiments in several laboratories. The cloning and chromosomal localization to chromosome 2p21 of the two human gonadotropin receptor genes has provided insights into their evolutionary relationships. The LHR and FSHR genes are very large and contain 10 and 11 exons respectively. The obtention of monoclonal antibodies against the receptors resulted in the characterization of the receptor proteins. These antibodies also allowed the study of receptor expression in target cells in physiological and pathological conditions. The internalization of the LHR has been studied by electron microscopy. A mechanism of receptor-mediated transcytosis through the endothelial cells of the testes has been described for the LHR. The polarized expression of receptors has been studied. The cloning of gonadotropin receptor genes has opened the field of genetic study of the receptors. Inactivating mutations of the LHR have been described in Leydig cell agenesis or hypoplasia. Different phenotypes, including complete pseudohermaphroditism, ambiguous genitalia and male phenotype, have been described. In the case of the FSHR, only one mutation has been reported in familial ovarian dysgenesis with primary amenorrhea. Related males have variable alterations of spermatogenesis and fertility. Constitutive mutations of the LHR have been reported in familial testotoxicosis. One similar mutation has also been described for the FSHR. Such mutations may lead to the development of a model of receptor activation.


Subject(s)
Ovary/physiology , Receptors, Gonadotropin/physiology , Testis/physiology , Female , Humans , Immunohistochemistry , Leydig Cells/pathology , Male , Ovary/embryology , Receptors, FSH/chemistry , Receptors, FSH/genetics , Receptors, Gonadotropin/chemistry , Receptors, Gonadotropin/genetics , Receptors, LH/chemistry , Receptors, LH/genetics , Receptors, Thyrotropin/chemistry , Receptors, Thyrotropin/genetics , Structure-Activity Relationship , Testis/embryology
12.
J Clin Endocrinol Metab ; 82(7): 2159-65, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9215288

ABSTRACT

We report the case of an infant who presented at birth with a hypoplastic phallus associated with hypospadias. Low testosterone production, normal serum levels of steroid precursors, and increased LH in response to LH-releasing hormone supported a defect in Leydig cell differentiation or function. Conventional microscopic study of the testes showed fibroblastic cells in the interstitium. However immunocytochemical analysis using anti-LH receptor and anti-P450c17 antibodies demonstrated that about one third of these cells were Leydig cells or precursors of Leydig cells. No histological feature could distinguish the latter cells from fibroblasts. A homozygous substitution of cysteine 133 for arginine was found in the extracellular domain of the receptor. This is the first naturally occurring missense mutation found in the extracellular domain of the LH receptor. COS-7 cells transfected with the mutant receptor exhibited a marked impairment of hCG binding, whereas some cAMP production could be observed at high hCG concentrations. We propose that the partial impairment of LH receptor function, as reflected by the presence of Leydig cells, was responsible for the incomplete male pseudohermaphroditism observed in our patient.


Subject(s)
Disorders of Sex Development/diagnosis , Gonads/anatomy & histology , Gonads/metabolism , Receptors, LH/metabolism , Animals , COS Cells , Cyclic AMP/metabolism , Cytochrome P-450 Enzyme System/metabolism , Disorders of Sex Development/genetics , Humans , Immunohistochemistry , Infant, Newborn , Male , Pedigree , Receptors, LH/genetics , Steroid 17-alpha-Hydroxylase/metabolism , Transfection
13.
J Biol Chem ; 272(8): 5241-8, 1997 Feb 21.
Article in English | MEDLINE | ID: mdl-9030595

ABSTRACT

The thyrotropin (TSH) and follicle-stimulating hormone (FSH) receptors are present mainly on the basolateral cell surface in the thyroid gland and in Sertoli cells, whereas in ovarian and in testicular cells, the luteinizing hormone (LH) receptors are distributed throughout the cell surface. When expressed in Madin-Darby canine kidney (MDCK) cells, all three receptors accumulated at the basolateral cell surface showing that they carry the corresponding targeting signals. The receptors were directly delivered to the basolateral surface of the MDCK cells. A minor fraction of the gonadotropin receptors but not of TSH receptors was secondarily targeted to the apical surface through transcytosis. The mechanisms of basolateral targeting and transcytosis were analyzed using the FSH receptor as a model. Both were insensitive to brefeldin A and pertussis toxin. Gs activation by AlF4- and cholera toxin provoked a marked enhancement of FSH receptor transcytosis. The population of Gs proteins involved in this mechanism was different from that involved in signal transduction since neither FSH nor forskolin mimicked the effects of AlF4- and cholera toxin. Gs activation provoked a similar effect on LH receptor distribution in MDCK cells, whereas it did not modify the compartmentalization of the TSH receptor. Hormone-specific transcytosis was observed in MDCK cells expressing the gonadotropin (FSH and LH) receptors and was increased after cholera toxin administration.


Subject(s)
Gonadotropins/metabolism , Kidney/metabolism , Receptors, Thyrotropin/metabolism , Animals , Biological Transport , Cell Line , Dogs , Gene Expression , Gonadotropins/genetics , Receptors, Thyrotropin/genetics , Transfection
14.
Horm Res ; 48 Suppl 4: 33-7, 1997.
Article in English | MEDLINE | ID: mdl-9350444

ABSTRACT

Gonadotrophin and thyrotrophin receptors belong to a subgroup of G-protein-coupled receptors. These receptors are characterized by a large extracellular domain that is responsible for the binding of the hormone. Soluble receptors, such as some luteinizing hormone receptors, arise from premessenger RNA alternative splicing, or, in the case of thyroid-stimulating hormone (TSH) receptors, by the cleavage and shedding of the ectodomain. Follicle-stimulating hormone and TSH receptors are restricted to the basolateral domain of their target cells. These receptors are also present in endothelial cells of target organ vessels and are involved in hormone transcytosis. Various genetic abnormalities of these receptors have been described.


Subject(s)
Receptors, FSH/physiology , Receptors, LH/physiology , Receptors, Thyrotropin/physiology , Alternative Splicing , Endothelium, Vascular/physiology , GTP-Binding Proteins/metabolism , Graves Disease/physiopathology , Humans , Male , RNA Precursors/metabolism , Receptors, FSH/analysis , Receptors, FSH/biosynthesis , Receptors, LH/analysis , Receptors, LH/biosynthesis , Receptors, Thyrotropin/analysis , Receptors, Thyrotropin/biosynthesis
15.
Mol Cell Endocrinol ; 125(1-2): 161-7, 1996 Dec 20.
Article in English | MEDLINE | ID: mdl-9027354

ABSTRACT

Monoclonal antibodies have been raised against the LH/CG receptor [1] and have allowed to perform immunochemical studies of the receptor in target cells. Three different forms of the LH/CG receptor are physiologically expressed: a mature approximately 85 kDa transmembrane species corresponding to the full length receptor, a approximately 68 kDa high mannose containing species corresponding to a precursor which accumulates inside the cells, and truncated soluble approximately 45-48 kDa molecular weight species corresponding to the variant messanger RNAs generated by alternative splicing. Monoclonal antibodies against the human FSH receptor were also prepared. They allow to observe the existence of two forms of the FSH receptor in the ovaries: a major approximately 87 kDa species corresponding to the mature receptor and a minor approximately 81 kDa species corresponding to a high mannose rich precursor. No variant forms of the receptor corresponding to alternative mRNA transcripts were detected. The transport of hCG was examined in rat testicular microvasculature by electron microscopy and by analyzing the transfer of radiolabeled hormone and antireceptor antibodies. LH/CG receptors were present in endothelial cells and were involved in hormone transcytosis through these cells. Immunocytochemical experiments have shown that the FSH receptor has a polarized expression in the Sertoli cells of the testes whereas the LH/Cg receptor is spread on the surface of thecal granulosa and luteal cells in the ovary and Leydig cells in the testes. To study the mechanism of this polarization FSH, LH and TSH receptors were expressed in polarized MDCK cells. The mechanism of basolateral localization and of transcytosis of the receptors was studied using this model. The effect of hormone, cAMP and agents acting on G proteins was examined.


Subject(s)
Receptors, FSH/chemistry , Receptors, LH/chemistry , Animals , Cloning, Molecular , Genetic Variation , Humans , Molecular Structure , Receptors, FSH/analysis , Receptors, FSH/genetics , Receptors, LH/analysis , Receptors, LH/genetics
16.
Exp Cell Res ; 218(2): 531-9, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7796887

ABSTRACT

Retinoic acid-induced heparin binding protein (RIHB) is a highly basic, secreted polypeptide expressed during early chick embryogenesis. We have characterized the binding of 125I-labeled RIHB to embryonal chondrocytes in culture. No saturable, high-affinity binding can be observed on these cells. Furthermore, no 125I-labeled RIHB was internalized into the chondrocytes at 37 degrees C. The low-affinity binding of 125I-labeled RIHB observed can be competed with another heparin binding factor, fibroblast growth factor 2, as efficiently as with unlabeled RIHB. The binding can also be almost completely inhibited by preincubation of the 125I-labeled RIHB with heparin or with a monoclonal antibody which recognizes the heparin binding site of both RIHB and HBNF. When cross-linking experiments are performed with 125I-labeled RIHB, specific RIHB-containing high-molecular-weight complexes are observed; however, these represent only a very small fraction of the bound material. Immunohistochemical analyses of embryonic wing cartilage demonstrate that a significant fraction of bound RIHB can be removed from unfixed tissue simply by rinsing with phosphate-buffered saline. The remaining RIHB can be removed partially by incubation with heparitinase I or III and completely when the incubation is performed with chondoitinase A, B, C. These results demonstrate that RIHB binds to embryonal chondrocytes and cartilage primarily through proteoglycans of both heparan sulfate and chondroitin sulfate types.


Subject(s)
Avian Proteins , Carrier Proteins/metabolism , Cartilage/metabolism , Proteoglycans/metabolism , Animals , Binding, Competitive , Cartilage/embryology , Cells, Cultured , Chick Embryo , Immunohistochemistry , Intracellular Signaling Peptides and Proteins , Radioligand Assay
17.
Langenbecks Arch Chir ; 362(3): 185-92, 1984.
Article in German | MEDLINE | ID: mdl-6381940

ABSTRACT

In experiments with dogs the influence of controlled respiration with positive endexpiratory pressure (PEEP) on the pancreas was investigated. The pO2 within the tissue was measured during the time of respiration. At PEEP 10 and PEEP 20 an average diminution was observed in the tissue pO2 of 27% and 37%, respectively. A pancreatic edema produced after PEEP 20 was changing into a necrotizing pancreatitis during the following 24 h. At PEEP 10, such a transition was not observed. The pancreatic edema was accompanied by the typical increase in alpha-amylase and lipase activities. After 24 h there were small changes of the enzyme activities in the serum at PEEP 10, whereas at PEEP 20 they were remarkably increased. These results demonstrate that PEEP 20 causes a shortage of oxygen supply of the pancreas. This shortage in connection with an edema can provoke an acute pancreatitis.


Subject(s)
Pancreatitis/etiology , Positive-Pressure Respiration/adverse effects , Acute Disease , Animals , Dogs , Edema/etiology , Edema/metabolism , Edema/pathology , Female , Male , Oxygen Consumption , Pancreas/metabolism , Pancreas/pathology , Pancreatitis/metabolism , Pancreatitis/pathology , Partial Pressure
SELECTION OF CITATIONS
SEARCH DETAIL
...